Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sun Pharma Advanced Research Co's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 108.07%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
NSE:SPARC's 3-Year ROIIC % is ranked better than 90.27% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs NSE:SPARC: 108.07
Sun Pharma Advanced Research Co (NSE:SPARC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sun Pharma Advanced Research Co 3-Year ROIIC % Related Terms
Sun Pharma Advanced Research Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co 3-Year ROIIC % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 15885.5 (Mar. 2026) - -2236.443 (Mar. 2023) )
/
( 20710.9 (Mar. 2026) - 3941.548 (Mar. 2023) )
=
18121.943
/
16769.352
=
108.07%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sun Pharma Advanced Research Co (NSE:SPARC) has a 3-Year ROIIC % of 108.07 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sun Pharma Advanced Research Co and its competitors. This is 453% above median its historical median of 19.56. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #92 out of 946 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is Sun Pharma Advanced Research Co's 3-Year ROIIC % too high?
Sun Pharma Advanced Research Co's current 3-Year ROIIC % of 108.07 is 453% above median its 10-year median of 19.56. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Sun Pharma Advanced Research Co's value of 108.07 is 2873% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #92 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #92 out of 946 companies for 3-Year ROIIC %. This places Sun Pharma Advanced Research Co in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Sun Pharma Advanced Research Co's value of 108.07 is 2873% above this benchmark. While the company's 10-year median is 19.56 vs. the industry median of 3.64, Sun Pharma Advanced Research Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current 3-Year ROIIC % of 108.07 is 2873% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current 3-Year ROIIC % is 108.07, which is 453% above median its own 10-year median of 19.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,530.69, compared to a current price of ₹247.83 — trading 94.5% below its estimated fair value. The current 3-Year ROIIC % is 108.07, which is 453% above median its 10-year median of 19.56 and 2873% above the Drug Manufacturers industry median of 3.64. Sun Pharma Advanced Research Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current 3-Year ROIIC % is 108.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued.
The current stock price of ₹247.83 is trading 94.5% below its estimated GF Value™ of ₹4,530.69.
GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.
Key valuation signals for NSE:SPARC:
3-Year ROIIC %: 108.07 (453% above median its 10-year median of 19.56)
GF Value™: ₹4,530.69 vs. price of ₹247.83 (94.5% below fair value)
Industry Position: 2873% above the Drug Manufacturers median (#92 of 946)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
62GF Score
Get the complete analysis for NSE:SPARC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
